Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Phase 1

• Conditions: Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome With Gene Mutation; Myeloproliferative Neoplasm; Acute Myeloid Leukemia With Gene Mutations
• Interventions: Drug: APR-246; Drug: Azacitidine

• Registration Number: NCT03588078
• Lead Sponsor: Groupe Francophone des Myelodysplasies

Brief Summary

The main purpose of this study is to determine the safe and efficacy of APR-246 in combination with azacitidine as well as to see complete remission of this patients

Detailed Description

Patients will be treated for a total of 6 cycles.For patients responding or who have stable disease following cycle 6, treatment may continue until one of the following criteria applies:

* Inter-current illness that prevent further administration of treatment

* Unacceptable adverse event(s)

* Participant decides to withdraw from the study,

* general or specific changes in the participant's condition render the participant unacceptable for further treatment in the judgment of the investigator.

* Evidence of disease progression by international working Group (IWG) 2006 criteria.

* participants who wish not to continue treatment at time of disease assessment at end of cycle 6 will complete their end of treatment visit upon completion of cycle 6

Study Timeline

• Study First Submitted: 2018-06-20
• Study First Submitted QC: 2018-07-03
• Study First Posted: 2018-07-17
• Study Start: 2018-09-15
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-29
• Last Update Posted: 2020-01-30
• Primary Completion: 2020-05-01
• Study Completion: 2021-05-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 53

Inclusion Criteria

1. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.

2. Patient has adequate organ function as defined by the following laboratory values:

   1. Serum creatinine ≤ 2 x upper limit of normal (ULN)
   2. Total serum bilirubin < 1.5 x ULN or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome or hemolysis or who required regular blood transfusions
   3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN

3. Age ≥18 years at the time of signing the informed consent form

4. Documented diagnosis of myelodysplastic syndrome (MDS), MDS/ myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML) by World Health organization (WHO) criteria or non-proliferative AML (ie with WBC < 20 G/l)

5. Documentation of a TP53 gene mutation by next-generation sequencing (NGS) based on central or local evaluation.

6. Revised International Prognostic Scoring System (IPSS-R) criteria for Intermediate, High-risk or Very High-risk.

7. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 is required.

8. If of childbearing potential, negative pre-treatment urine or serum pregnancy test.

9. If of childbearing potential (males and females), willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter.

Exclusion Criteria

1. Patient has a known history of HIV or active hepatitis B or active hepatitis C infection (testing not mandatory).

2. Patient has any of the following cardiac abnormalities (as determined by treating MD):

   1. symptomatic congestive heart failure
   2. myocardial infarction ≤ 6 months prior to enrollment
   3. unstable angina pectoris
   4. serious uncontrolled cardiac arrhythmia
   5. QTc ≥ 470 msec (≥ 500 msec in the presence of RBBB) calculated from a mean of 3 ECG readings using Fridericia's correction (QTcF = QT/RR0.33)
   6. bradycardia (<40 bpm)
   7. known left ventricular ejection fraction (LVEF) < the institution lower limit of normal as assessed by ECHO
   8. clinically significant pericardial disease
   9. electrocardiographic evidence of acute ischemia
   10. familial history of long QT syndrome

3. Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis.

4. Prior exposure to azacitidine, decitabine or investigational hypomethylating agent

5. Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS, MDS/MPN, CMML or AML within 14 days of the first day of study drug treatment.

6. No concurrent use of erythroid stimulating agents, Granulocyte-colony stimulating Factor (G-CSF), Granulocyte Macrophage-colony stimulating factor (GM-CSF) is allowed during study except in cases of febrile neutropenia where G-CSF can be used for short term. Growth factors must be stopped 14 days prior to study.

7. Patients with history of allogeneic stem cell transplantation.

8. Pregnant women are excluded from this study because APR-246 has not been studied in pregnant subjects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR-246, breastfeeding should be discontinued if the mother is treated with APR-246.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
combination of APR246 and azacitidine	Azacitidine	Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
combination of APR246 and azacitidine	APR-246	Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b

Primary Outcome Measures

Name	Time	Method
Overall Survival	8 months	overall survival at complete remission

Secondary Outcome Measures

Name	Time	Method
Duration of response	minimum 24 months it is defined as the time between achieving response and progression of disease

Trial Locations

Locations (7)

Odile Beyne Rosy; 🇫🇷 Toulouse, France

Hôpital Cochin/Service d'Hématologie; 🇫🇷 Paris, France

Aspasia Stamatoullas; 🇫🇷 Rouen, France

Hôpital Saint Louis - Hématologie Séniors; 🇫🇷 Paris, France

Dr Pierre Peterlin and Pr Patrice Chevalier; 🇫🇷 Nantes, France

Hôpital Archet 1; 🇫🇷 Nice, France

Bruno Quesnel; 🇫🇷 Lille, France